Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Seitz

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Cell Cycle (Georgetown, Tex.)|July 4, 2012
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancersFerenc G Rick, Stefan Buchholz, Andrew V Schally, et al.
Journal of Cancer Research and Clinical Oncology|July 7, 2023
Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?Maria Eleni Hatzipanagiotou, Miriam Pigerl, Michael Gerken, et al.
Cancer Cell International|March 28, 2025
Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapyVerena Schweihofer, Christina Bruss, Stephan Seitz, et al.
JCO Precision Oncology|September 27, 2021
<i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential TherapyValeria Gerthofer, Alexander Scheiter, Florian Lüke, et al.
Breast Cancer Research and Treatment|September 8, 2023
Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA studySteffi Hartmann, Maggie Banys-Paluchowski, Elmar Stickeler, et al.
International Journal of Oncology|September 3, 2009
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibitionStefan Buchholz, Stephan Seitz, Andrew V Schally, et al.
BMC Cancer|November 21, 2014
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125Stephan Seitz, Stefan Buchholz, Andrew Victor Schally, et al.
Frontiers in Oncology|May 3, 2024
App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trialJosefine Wolff, Svenja Seidel, Pia Wuelfing, et al.
Cancer|June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance surveyNathalie Rippinger, Christine Fischer, Markus W Haun, et al.
Geburtshilfe Und Frauenheilkunde|January 29, 2019
Concept Paper on the Technique of Cryopreservation, Removal and Transplantation of Ovarian Tissue for Fertility PreservationMatthias W Beckmann, Laura Lotz, Bettina Toth, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Cell Cycle (Georgetown, Tex.)|July 4, 2012
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancersFerenc G Rick, Stefan Buchholz, Andrew V Schally, et al.
Journal of Cancer Research and Clinical Oncology|July 7, 2023
Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?Maria Eleni Hatzipanagiotou, Miriam Pigerl, Michael Gerken, et al.
Cancer Cell International|March 28, 2025
Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapyVerena Schweihofer, Christina Bruss, Stephan Seitz, et al.
JCO Precision Oncology|September 27, 2021
<i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential TherapyValeria Gerthofer, Alexander Scheiter, Florian Lüke, et al.
Breast Cancer Research and Treatment|September 8, 2023
Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA studySteffi Hartmann, Maggie Banys-Paluchowski, Elmar Stickeler, et al.
International Journal of Oncology|September 3, 2009
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibitionStefan Buchholz, Stephan Seitz, Andrew V Schally, et al.
BMC Cancer|November 21, 2014
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125Stephan Seitz, Stefan Buchholz, Andrew Victor Schally, et al.
Frontiers in Oncology|May 3, 2024
App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trialJosefine Wolff, Svenja Seidel, Pia Wuelfing, et al.
Cancer|June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance surveyNathalie Rippinger, Christine Fischer, Markus W Haun, et al.
Geburtshilfe Und Frauenheilkunde|January 29, 2019
Concept Paper on the Technique of Cryopreservation, Removal and Transplantation of Ovarian Tissue for Fertility PreservationMatthias W Beckmann, Laura Lotz, Bettina Toth, et al.
Pageof 6